ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, Against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and with Defined Extended-Spectrum β-Lactamases and Carbapenemases

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2018 Oct 17

PMID 30323050

Citations 59

Authors

Michael R Jacobs

Ayman M Abdelhamed

Caryn E Good

Daniel D Rhoads

Kristine M Hujer

Andrea M Hujer

T Nicholas Domitrovic

Susan D Rudin

Sandra S Richter

David van Duin

Barry N Kreiswirth

Chris Greco

Derrick E Fouts

Robert A Bonomo

Affiliations

Soon will be listed here.

Abstract

The activity of the siderophore cephalosporin cefiderocol is targeted against carbapenem-resistant Gram-negative bacteria. In this study, the activity of cefiderocol against characterized carbapenem-resistant complex, , , and strains was determined by microdilution in iron-depleted Mueller-Hinton broth. The MICs against , , and were 1, 0.25, and 0.5 mg/liter, respectively. Against , the MIC was 1 mg/liter for the group harboring OXA-48-like, 2 mg/liter for the group harboring KPC-3, and 8 mg/liter for the group harboring TEM/SHV ESBL, NDM, and KPC-2.

Citing Articles

ARGONAUT-IV: susceptibility of carbapenemase-producing to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten.

Jacobs M, Good C, Abdelhamed A, Mack A, Bethel C, Marshall S Antimicrob Agents Chemother. 2024; 68(12):e0112724.

PMID: 39475259 PMC: 11619242. DOI: 10.1128/aac.01127-24.

Effects of different carbapenemase and siderophore production on cefiderocol susceptibility in .

Yang C, Wang L, Lv J, Wen Y, Gao Q, Qian F Antimicrob Agents Chemother. 2024; 68(12):e0101924.

PMID: 39470196 PMC: 11619314. DOI: 10.1128/aac.01019-24.

In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.

Boattini M, Bianco G, Comini S, Costa C, Gaibani P Eur J Clin Microbiol Infect Dis. 2024; 43(12):2407-2417.

PMID: 39384682 PMC: 11608324. DOI: 10.1007/s10096-024-04958-w.

Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.

Kirkegaard-Biosca C, Barrio-Tofino E, Villamarin M, Larrosa N, Campany D, Gonzalez-Lopez J Antibiotics (Basel). 2024; 13(9.

PMID: 39335047 PMC: 11428964. DOI: 10.3390/antibiotics13090874.

Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria.

Chiang A, Dekker J Commun Med (Lond). 2024; 4(1):170.

PMID: 39210044 PMC: 11362173. DOI: 10.1038/s43856-024-00591-y.

References

Katsube T, Miyazaki S, Narukawa Y, Hernandez-Illas M, Wajima T . Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters. Eur J Clin Pharmacol. 2018; 74(7):931-938. DOI: 10.1007/s00228-018-2458-9. View

Ghazi I, Monogue M, Tsuji M, Nicolau D . Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model. Int J Antimicrob Agents. 2017; 51(2):206-212. DOI: 10.1016/j.ijantimicag.2017.10.008. View

Wright H, Bonomo R, Paterson D . New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?. Clin Microbiol Infect. 2017; 23(10):704-712. DOI: 10.1016/j.cmi.2017.09.001. View

Katsube T, Echols R, Ferreira J, Krenz H, Berg J, Galloway C . Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment. J Clin Pharmacol. 2016; 57(5):584-591. PMC: 5412848. DOI: 10.1002/jcph.841. View

Hackel M, Tsuji M, Yamano Y, Echols R, Karlowsky J, Sahm D . Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother. 2017; 61(9. PMC: 5571285. DOI: 10.1128/AAC.00093-17. View

Poirel L, Walsh T, Cuvillier V, Nordmann P . Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011; 70(1):119-23. DOI: 10.1016/j.diagmicrobio.2010.12.002. View

Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R . Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016; 60(12):7396-7401. PMC: 5119021. DOI: 10.1128/AAC.01405-16. View

Huband M, Ito A, Tsuji M, Sader H, Fedler K, Flamm R . Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design. Diagn Microbiol Infect Dis. 2017; 88(2):198-200. DOI: 10.1016/j.diagmicrobio.2017.03.011. View

Perez F, Hujer A, Marshall S, Ray A, Rather P, Suwantarat N . Extensively drug-resistant pseudomonas aeruginosa isolates containing blaVIM-2 and elements of Salmonella genomic island 2: a new genetic resistance determinant in Northeast Ohio. Antimicrob Agents Chemother. 2014; 58(10):5929-35. PMC: 4187935. DOI: 10.1128/AAC.02372-14. View

10.

Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T . In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains. Antimicrob Agents Chemother. 2015; 60(2):729-34. PMC: 4750680. DOI: 10.1128/AAC.01695-15. View

11.

Endimiani A, Hujer A, Perez F, Bethel C, Hujer K, Kroeger J . Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother. 2009; 63(3):427-37. PMC: 2640158. DOI: 10.1093/jac/dkn547. View

12.

Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S . Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740388. DOI: 10.1128/AAC.01454-17. View

13.

Ito A, Kohira N, Bouchillon S, West J, Rittenhouse S, Sader H . In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother. 2015; 71(3):670-7. DOI: 10.1093/jac/dkv402. View

14.

Hackel M, Tsuji M, Yamano Y, Echols R, Karlowsky J, Sahm D . Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2017; 62(2). PMC: 5786755. DOI: 10.1128/AAC.01968-17. View

15.

Mojica M, Papp-Wallace K, Taracila M, Barnes M, Rutter J, Jacobs M . Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam. Antimicrob Agents Chemother. 2017; 61(10). PMC: 5610502. DOI: 10.1128/AAC.00777-17. View

16.

Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki E, Zaslavsky L . NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res. 2016; 44(14):6614-24. PMC: 5001611. DOI: 10.1093/nar/gkw569. View

17.

Evans S, Tran T, Hujer A, Hill C, Hujer K, Mediavilla J . Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. Clin Infect Dis. 2018; 68(11):1823-1830. PMC: 6938201. DOI: 10.1093/cid/ciy801. View

18.

Evans S, Hujer A, Jiang H, Hill C, Hujer K, Mediavilla J . Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III. J Clin Microbiol. 2016; 55(1):134-144. PMC: 5228224. DOI: 10.1128/JCM.01524-16. View

19.

Matsumoto S, Singley C, Hoover J, Nakamura R, Echols R, Rittenhouse S . Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics. Antimicrob Agents Chemother. 2017; 61(9). PMC: 5571323. DOI: 10.1128/AAC.00700-17. View

20.

Wright M, Iovleva A, Jacobs M, Bonomo R, Adams M . Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment. Genome Med. 2016; 8(1):26. PMC: 4776386. DOI: 10.1186/s13073-016-0279-y. View